ZoomMed Announces a Financing and the Issuance of Shares

ZoomMed Inc. (TSX VENTURE:ZMD) (the "Company" or "ZoomMed") announces it has
signed a term sheet with regards to a four million dollar ($4,000,000)
non-convertible debenture financing, subject to due diligence with a
Toronto-based investment firm. Subject to the approval of the TSX Venture
Exchange and the regulatory authorities, ZoomMed will issue to MSU Securities
Law Professional Corporation ("MSU") five hundred and eight thousand seven
hundred and eighty-six (508,786) common shares of the Company at a deemed price
of five cents ($0.05) per common share, as compensation for legal due diligence
services rendered within the scope of the financing. ZoomMed deals at arm's
length with MSU.


ZoomMed will use the net proceeds of the financing to fund growth capital
requirements.


About ZoomMed

The Company builds and operates "ZoomMed's communication network", a clinical
information exchange platform between physicians and the various other
stakeholders of the healthcare sector, such as pharmacists, specialists,
pharmaceutical corporations, laboratories, specialized clinics and others. The
cornerstone of this network is ZoomMed's "ZRx Prescriber", a technological
innovative Web application that enables physicians to use a wireless device,
such as IPhone(TM), IPad(TM), Google Android(TM) or computers, to write and
rapidly deliver scripts. Since it is a stand-alone product, it can easily be
integrated to any Electronic Medical Record application (EMR).


The Company also offers "PraxisLab", a new pharmacy management software that
enhances all aspects of the prescription filling process and the complete
pharmacy patient file management.


Moreover, the Company holds 50% of the equity share of an American Joint Venture
which commercializes throughout North America, "EvPsych" an Electronic Medical
Record (EMR) designed for all behavioural health providers.


About MSU Securities Law Professional Corporation

MSU is a Toronto-based law firm specializing in corporate and securities law
with a focus on small and mid cap companies. For more information:
[e-mail] 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. Statements made in this news release
that are not historical facts are "forward-looking statements" and readers are
cautioned that any such statements are not guarantees of future performance, and
that actual developments or results, may vary materially from those in these
"forward-looking" statement.


FOR FURTHER INFORMATION PLEASE CONTACT: 
ZoomMed
Yves Marmet
President and Chief Executive Officer
[phone], Ext 228
[e-mail]
www.zoommed.com